On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

From the moment the first rate cut occurred, long-term interest rates ... “You know, I want to own, I want to own CRISPR because I keep seeing their name come up and all the science papers ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Using CRISPR technology, scientists uncovered genes that control C-A-G genetic stumbles in Huntington's disease ...

In addition, first-generation CRISPR systems (Cas9 and Cas12a) are too large for efficient in vivo delivery via a single adeno-associated viral (AAV) vector. Now, new preclinical research ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Recent scientific discoveries include the identification of an ancient Antarctic bird as the oldest 'modern' bird, revelations about moon canyons formed by asteroid impact, Chile's struggle with light ...

StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Barclays cut their price target on shares of CRISPR Therapeutics from $59.00 to $55. ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... He pointed out that ever since the Federal Reserve began cutting short-term rates in September 2024 ...